Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Closing remarks and treatment guidelines.

M Piccart1

  • 1Institut Jules Bordet, Unité de Chimiotherapie, 1 Rue Héger Bordet, B-1000 Brussels, Belgium. piccart@ulb.ac.be

European Journal of Cancer (Oxford, England : 1990)
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance.

ESMO open·2025
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2025
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

HER2 testing is crucial for breast cancer management. Accurate HER2 status determination guides treatment decisions, particularly with targeted therapies like trastuzumab, improving patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The human epidermal growth factor receptor 2 (HER2) is a key protein in breast cancer development.
  • HER2 overexpression drives tumor growth and is a target for therapy.

Purpose of the Study:

  • To highlight the clinical significance of HER2 status in breast cancer management.
  • To emphasize the need for standardized and reproducible HER2 testing.

Main Methods:

  • Review of clinical data and prospective trials involving HER2-targeted therapies.
  • Analysis of treatment algorithms incorporating HER2 status.

Main Results:

  • Trastuzumab, an anti-HER2 antibody, improves survival in HER2-positive metastatic breast cancer.

Related Experiment Videos

  • HER2 status has direct implications for optimal breast cancer patient management.

    • Conclusions:

    • Accurate HER2 testing is essential for guiding breast cancer treatment.
    • Standardizing HER2 testing is a priority to minimize errors and improve clinical practice.